1
|
Wang H, Zhao X, Wu Z. Mechanism of drug-pairs Astragalus Mongholicus-Largehead Atractylodes on treating knee osteoarthritis investigated by GEO gene chip with network pharmacology and molecular docking. Medicine (Baltimore) 2024; 103:e38699. [PMID: 38968529 PMCID: PMC11224889 DOI: 10.1097/md.0000000000038699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Accepted: 06/04/2024] [Indexed: 07/07/2024] Open
Abstract
Investigations into the therapeutic potential of Astragalus Mongholicus (AM, huáng qí) and Largehead Atractylodes (LA, bái zhú) reveal significant efficacy in mitigating the onset and progression of knee osteoarthritis (KOA), albeit with an elusive mechanistic understanding. This study delineates the primary bioactive constituents and their molecular targets within the AM-LA synergy by harnessing the comprehensive Traditional Chinese Medicine (TCM) network databases, including TCMSP, TCMID, and ETCM. Furthermore, an analysis of 3 gene expression datasets, sourced from the gene expression omnibus database, facilitated the identification of differential genes associated with KOA. Integrating these findings with data from 5 predominant databases yielded a refined list of KOA-associated targets, which were subsequently aligned with the gene signatures corresponding to AM and LA treatment. Through this alignment, specific molecular targets pertinent to the AM-LA therapeutic axis were elucidated. The construction of a protein-protein interaction network, leveraging the shared genetic markers between KOA pathology and AM-LA intervention, enabled the identification of pivotal molecular targets via the topological analysis facilitated by CytoNCA plugins. Subsequent GO and KEGG enrichment analyses fostered the development of a holistic herbal-ingredient-target network and a core target-signal pathway network. Molecular docking techniques were employed to validate the interaction between 5 central molecular targets and their corresponding active compounds within the AM-LA complex. Our findings suggest that the AM-LA combination modulates key biological processes, including cellular activity, reactive oxygen species modification, metabolic regulation, and the activation of systemic immunity. By either augmenting or attenuating crucial signaling pathways, such as MAPK, calcium, and PI3K/AKT pathways, the AM-LA dyad orchestrates a comprehensive regulatory effect on immune-inflammatory responses, cellular proliferation, differentiation, apoptosis, and antioxidant defenses, offering a novel therapeutic avenue for KOA management. This study, underpinned by gene expression omnibus gene chip analyses and network pharmacology, advances our understanding of the molecular underpinnings governing the inhibitory effects of AM and LA on KOA progression, laying the groundwork for future explorations into the active components and mechanistic pathways of TCM in KOA treatment.
Collapse
Affiliation(s)
- Hui Wang
- Jinan Third People’s Hospital, Affiliated Jinan Third People’s Hospital of Jining Medical University, Jining, Shandong, China
| | - Xinyou Zhao
- Yanzhou People’s Hospital, Jining Medical University, Jining, Shandong, China
| | - Zixuan Wu
- Hunan University of Traditional Chinese Medicine, Changsha, Hunan Province, China
| |
Collapse
|
2
|
Yang T, Cao T, Yang X, Wang G, Li Y. Elucidation of the key therapeutic targets and potential mechanisms of Andrographolide multi-targets against osteoarthritis via network pharmacological analysis and experimental validation. Gene 2024; 911:148351. [PMID: 38462021 DOI: 10.1016/j.gene.2024.148351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2023] [Revised: 02/26/2024] [Accepted: 03/07/2024] [Indexed: 03/12/2024]
Abstract
OBJECTIVE Our purpose is to unveil Andrographolide's potential multi-target and multi-mechanism therapeutic effects in treating OA via systematic network pharmacological analysis and cell experimental validation. MATERIALS AND METHODS Initially, we gathered data from Andrographolide and OA-related databases to obtain information on Andrographolide's biological properties and the targets linked with OA. We developed a bioinformatic network about Andrographolide and OA, whereby we analyzed the network to identify potential therapeutic targets and mechanisms of action of Andrographolide. Subsequently, we used molecular docking to analyze the binding sites of Andrographolide to the target proteins. At the same time, SDF-1 was used to construct an OA cell model to verify the therapeutic effect of Andrographolide on OA and its effect on target proteins. RESULTS Our experimental results show that Andrographolide has excellent pharmaceutical properties, by Lipinski's rules for drugs, suggesting that this compound can be considered to have a high therapeutic potential in drug development. 233 targets were preliminarily investigated, the mechanisms through which Andrographolide targets OA primarily involve the TNF signaling pathway, PI3K-AKT signaling pathway, IL-17 signaling pathway, and TLR signaling pathway. These mechanisms target OA by influencing immune and inflammatory responses in the joints, regulating apoptosis to prevent chondrocyte death. Finally, TNF-α, STAT3, TP53, IL-6, JUN, IL-1β, HIF-1α, TGF-β1, and AKT1 were identified as 9 key targets of Andrographolide anti-OA. In addition, our molecular docking analyzes with cell experimental validation further confirm the network pharmacology results. According to our molecular docking results, Andrographolide can bind to all the hub target proteins and has a good binding ability (binding energy < -5 kcal/mol), with the strongest binding affinity to AKT1 of -9.2 kcal/ mol. The results of cell experiments showed that Andrographolide treatment significantly increased the cell viability and the expression of COL2A1 and ACAN proteins. Moreover, 30 μM Andrographolide significantly reversed SDF-1-induced increases in the protein expression of TNF-α, STAT3, TP53, IL-6, JUN, IL-1β, HIF-1α, and TGF-β1, and decreases in the protein expression of AKT1. CONCLUSION This study provides a comprehensive understanding of the potential therapeutic targets and mechanisms of action of Andrographolide in OA treatment. Our findings suggest that Andrographolide is a promising candidate for drug development in the management of OA.
Collapse
Affiliation(s)
- Tengyun Yang
- Department of Sports Medicine, The First Affiliated Hospital, Kunming Medical University, Kunming, 650032, Yunnan, China
| | - Tingting Cao
- School of Pharmaceutical Science and Yunnan Key Laboratory of Pharmacology of Natural Products, Kunming Medical University, Kunming, 650500, Yunnan, China
| | - Xianguang Yang
- Department of Sports Medicine, The First Affiliated Hospital, Kunming Medical University, Kunming, 650032, Yunnan, China
| | - Guoliang Wang
- Department of Sports Medicine, The First Affiliated Hospital, Kunming Medical University, Kunming, 650032, Yunnan, China
| | - Yanlin Li
- Department of Sports Medicine, The First Affiliated Hospital, Kunming Medical University, Kunming, 650032, Yunnan, China.
| |
Collapse
|
3
|
Tong X, Wang Y, Dong B, Li Y, Lang S, Ma J, Ma X. Effects of genus Epimedium in the treatment of osteoarthritis and relevant signaling pathways. Chin Med 2023; 18:92. [PMID: 37525296 PMCID: PMC10388486 DOI: 10.1186/s13020-023-00788-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Accepted: 06/25/2023] [Indexed: 08/02/2023] Open
Abstract
Osteoarthritis (OA) is a common chronic degenerative joint disease in clinical practice with a high prevalence, especially in the elderly. Traditional Chinese Medicine (TCM) believes that OA belongs to the category of "Bi syndrome" and the "bone Bi syndrome". The etiology and pathogenesis lie in the deficiency of the liver and kidney, the deficiency of Qi and blood, and external exposure to wind, cold, and dampness. Epimedium is a yang-reinforcing herb in TCM, which can tonify the liver and kidney, strengthen muscles and bones, dispel wind, cold and dampness, and can treat both the symptoms and the root cause of "bone Bi syndrome". In addition, Epimedium contains a large number of ingredients. Through modern science and technology, more than 270 compounds have been found in Epimedium, among which flavonoids are the main active ingredients. Therefore, our study will review the effects and mechanisms of genus Epimedium in treating OA from two aspects: (1) Introduction of Epimedium and its main active ingredients; (2) Effects of Epimedium and its active ingredients in treating OA and relevant signaling pathways, in order to provide more ideas for OA treatment.
Collapse
Affiliation(s)
- Xue Tong
- Orthopaedics Institute of Tianjin, Tianjin Hospital, Tianjin, China
- School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
- Tianjin Hospital, Tianjin University, Tianjin, China
| | - Yan Wang
- Orthopaedics Institute of Tianjin, Tianjin Hospital, Tianjin, China
- Tianjin Hospital, Tianjin University, Tianjin, China
| | - Benchao Dong
- Orthopaedics Institute of Tianjin, Tianjin Hospital, Tianjin, China
- Tianjin Hospital, Tianjin University, Tianjin, China
| | - Yan Li
- Orthopaedics Institute of Tianjin, Tianjin Hospital, Tianjin, China
- Tianjin Hospital, Tianjin University, Tianjin, China
| | - Shuang Lang
- Orthopaedics Institute of Tianjin, Tianjin Hospital, Tianjin, China
- School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China
- Tianjin Hospital, Tianjin University, Tianjin, China
| | - Jianxiong Ma
- Orthopaedics Institute of Tianjin, Tianjin Hospital, Tianjin, China.
- Tianjin Hospital, Tianjin University, Tianjin, China.
| | - Xinlong Ma
- Orthopaedics Institute of Tianjin, Tianjin Hospital, Tianjin, China.
- Tianjin Hospital, Tianjin University, Tianjin, China.
| |
Collapse
|
4
|
Therapeutic potential of natural molecules against Alzheimer's disease via SIRT1 modulation. Biomed Pharmacother 2023; 161:114474. [PMID: 36878051 DOI: 10.1016/j.biopha.2023.114474] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2023] [Revised: 03/01/2023] [Accepted: 03/02/2023] [Indexed: 03/06/2023] Open
Abstract
Alzheimer's disease (AD) is a neurodegenerative disease mainly characterized by progressive cognitive dysfunction and memory impairment. Recent studies have shown that regulating silent information regulator 1 (SIRT1) expression has a significant neuroprotective effect, and SIRT1 may become a new therapeutic target for AD. Natural molecules are an important source of drug development for use in AD therapy and may regulate a wide range of biological events by regulating SIRT1 as well as other SIRT1-mediated signaling pathways. This review aims to summarize the correlation between SIRT1 and AD and to identify in vivo and in vitro studies investigating the anti-AD properties of natural molecules as modulators of SIRT1 and SIRT1-mediated signaling pathways. A literature search was conducted for studies published between January 2000 and October 2022 using various literature databases, including Web of Science, PubMed, Google Scholar, Science Direct, and EMBASE. Natural molecules, such as resveratrol, quercetin, icariin, bisdemethoxycurcumin, dihydromyricetin, salidroside, patchouli, sesamin, rhein, ligustilide, tetramethoxyflavanone, 1-theanine, schisandrin, curcumin, betaine, pterostilbene, ampelopsin, schisanhenol, and eriodictyol, have the potential to modulate SIRT1 and SIRT1 signaling pathways, thereby combating AD. The natural molecules modulating SIRT1 discussed in this review provide a potentially novel multi-mechanistic therapeutic strategy for AD. However, future clinical trials need to be conducted to further investigate their beneficial properties and to determine the safety and efficacy of SIRT1 natural activators against AD.
Collapse
|
5
|
Qin X, Zhou H, Wang X, Tian M, Dong Z, Wang C, Geng F, Huang Q. UHPLC‐Q‐Orbitrap HRMS Combined with Network Pharmacology to Explore the Mechanism of Chuanhuang Qingre Capsule in the Treatment of Acute Pharyngitis. ChemistrySelect 2022. [DOI: 10.1002/slct.202202539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Xiaoyan Qin
- State Key Laboratory of Southwestern Chinese Medicine Resources No.1166, Liutai Road, Wenjiang District Chengdu 611137 China
- College of Pharmacy Chengdu University of Traditional Chinese Medicine No.1166, Liutai Road, Wenjiang District Chengdu 611137 China
| | - Hailun Zhou
- State Key Laboratory of Southwestern Chinese Medicine Resources No.1166, Liutai Road, Wenjiang District Chengdu 611137 China
- College of Pharmacy Chengdu University of Traditional Chinese Medicine No.1166, Liutai Road, Wenjiang District Chengdu 611137 China
| | - Xi Wang
- State Key Laboratory of Southwestern Chinese Medicine Resources No.1166, Liutai Road, Wenjiang District Chengdu 611137 China
- College of Pharmacy Chengdu University of Traditional Chinese Medicine No.1166, Liutai Road, Wenjiang District Chengdu 611137 China
| | - Maoying Tian
- State Key Laboratory of Southwestern Chinese Medicine Resources No.1166, Liutai Road, Wenjiang District Chengdu 611137 China
- College of Pharmacy Chengdu University of Traditional Chinese Medicine No.1166, Liutai Road, Wenjiang District Chengdu 611137 China
| | - Zhaowei Dong
- State Key Laboratory of Southwestern Chinese Medicine Resources No.1166, Liutai Road, Wenjiang District Chengdu 611137 China
- College of Pharmacy Chengdu University of Traditional Chinese Medicine No.1166, Liutai Road, Wenjiang District Chengdu 611137 China
| | - Chao Wang
- Sichuan Integrated Traditional Chinese and Western Medicine Hospital, No.51, Section 4 Renmin South Road, Wuhou District Chengdu 610042 China
| | - Funeng Geng
- Sichuan Engineering Research Center for Medicinal Animals Jinhan Road, Shuangliu District Chengdu 611137 China
| | - Qinwan Huang
- State Key Laboratory of Southwestern Chinese Medicine Resources No.1166, Liutai Road, Wenjiang District Chengdu 611137 China
- College of Pharmacy Chengdu University of Traditional Chinese Medicine No.1166, Liutai Road, Wenjiang District Chengdu 611137 China
| |
Collapse
|